Catalyst Wire Dossier

Diseases Search Methodology Pricing Log in Sign up free

Diseases · Post-kala-azar Dermal Leishmaniasis

Post-kala-azar Dermal Leishmaniasis

📧 Sign up to get email alerts when something new happens for Post-kala-azar Dermal Leishmaniasis.

Top drugs studied for this disease

Impavido (3)
Miltefosine (2)
IVERMECTIN (2)
Three-Antigen Leishmania Polyprotein Vaccine with MPL-SE (1)
LEISH-F2 + MPL-SE vaccine with SSG (1)
Sodium stibogluconate (1)
AMBISOME (1)

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

No documents found for this filter.

Catalyst Wire Dossier

FDA, ClinicalTrials.gov, and EMA — organized by disease, AI-summarized. Daily updates.

Catalyst Wire family

Dossier SEC FDA Frontier Briefing

Stay updated

Website

Daily FDA actions. One-time €1 verification charge; no recurring payment. Confirm by email, unsubscribe anytime.

Data: openFDA, ClinicalTrials.gov, EMA. Analysis by GPT-5-nano. Not medical advice. · Methodology · Privacy · Terms